These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34837441)

  • 21. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy.
    Cowling BS; Chevremont T; Prokic I; Kretz C; Ferry A; Coirault C; Koutsopoulos O; Laugel V; Romero NB; Laporte J
    J Clin Invest; 2014 Mar; 124(3):1350-63. PubMed ID: 24569376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adult centronuclear myopathies: A hospital-based study.
    Echaniz-Laguna A; Biancalana V; Böhm J; Tranchant C; Mandel JL; Laporte J
    Rev Neurol (Paris); 2013; 169(8-9):625-31. PubMed ID: 23938035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Centronuclear myopathy with cataracts due to a novel dynamin 2 (DNM2) mutation.
    Jungbluth H; Cullup T; Lillis S; Zhou H; Abbs S; Sewry C; Muntoni F
    Neuromuscul Disord; 2010 Jan; 20(1):49-52. PubMed ID: 19932620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The dynamin-2-gene related centronuclear myopathy].
    Bitoun M
    Med Sci (Paris); 2023 Nov; 39 Hors série n° 1():6-10. PubMed ID: 37975763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model.
    Fongy A; Falcone S; Lainé J; Prudhon B; Martins-Bach A; Bitoun M
    Sci Rep; 2019 Feb; 9(1):1580. PubMed ID: 30733559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations.
    Böhm J; Biancalana V; Malfatti E; Dondaine N; Koch C; Vasli N; Kress W; Strittmatter M; Taratuto AL; Gonorazky H; Laforêt P; Maisonobe T; Olivé M; Gonzalez-Mera L; Fardeau M; Carrière N; Clavelou P; Eymard B; Bitoun M; Rendu J; Fauré J; Weis J; Mandel JL; Romero NB; Laporte J
    Brain; 2014 Dec; 137(Pt 12):3160-70. PubMed ID: 25260562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Muscle-specific function of the centronuclear myopathy and Charcot-Marie-Tooth neuropathy-associated dynamin 2 is required for proper lipid metabolism, mitochondria, muscle fibers, neuromuscular junctions and peripheral nerves.
    Tinelli E; Pereira JA; Suter U
    Hum Mol Genet; 2013 Nov; 22(21):4417-29. PubMed ID: 23813975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Satellite cells deficiency and defective regeneration in dynamin 2-related centronuclear myopathy.
    F Almeida C; Bitoun M; Vainzof M
    FASEB J; 2021 Apr; 35(4):e21346. PubMed ID: 33715228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy.
    Böhm J; Biancalana V; Dechene ET; Bitoun M; Pierson CR; Schaefer E; Karasoy H; Dempsey MA; Klein F; Dondaine N; Kretz C; Haumesser N; Poirson C; Toussaint A; Greenleaf RS; Barger MA; Mahoney LJ; Kang PB; Zanoteli E; Vissing J; Witting N; Echaniz-Laguna A; Wallgren-Pettersson C; Dowling J; Merlini L; Oldfors A; Bomme Ousager L; Melki J; Krause A; Jern C; Oliveira AS; Petit F; Jacquette A; Chaussenot A; Mowat D; Leheup B; Cristofano M; Poza Aldea JJ; Michel F; Furby A; Llona JE; Van Coster R; Bertini E; Urtizberea JA; Drouin-Garraud V; Béroud C; Prudhon B; Bedford M; Mathews K; Erby LA; Smith SA; Roggenbuck J; Crowe CA; Brennan Spitale A; Johal SC; Amato AA; Demmer LA; Jonas J; Darras BT; Bird TD; Laurino M; Welt SI; Trotter C; Guicheney P; Das S; Mandel JL; Beggs AH; Laporte J
    Hum Mutat; 2012 Jun; 33(6):949-59. PubMed ID: 22396310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy.
    Gibbs EM; Clarke NF; Rose K; Oates EC; Webster R; Feldman EL; Dowling JJ
    J Mol Med (Berl); 2013 Jun; 91(6):727-37. PubMed ID: 23338057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamin 2-related centronuclear myopathy: clinical, histological and genetic aspects of further patients and review of the literature.
    Jeub M; Bitoun M; Guicheney P; Kappes-Horn K; Strach K; Druschky KF; Weis J; Fischer D
    Clin Neuropathol; 2008; 27(6):430-8. PubMed ID: 19130742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myotonia in DNM2-related centronuclear myopathy.
    Dabby R; Sadeh M; Gilad R; Jurkat-Rott K; Lehmann-Horn F; Leshinsky-Silver E
    J Neural Transm (Vienna); 2014 May; 121(5):549-53. PubMed ID: 24366529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adult course in dynamin 2 dominant centronuclear myopathy with neonatal onset.
    Melberg A; Kretz C; Kalimo H; Wallgren-Pettersson C; Toussaint A; Böhm J; Stålberg E; Laporte J
    Neuromuscul Disord; 2010 Jan; 20(1):53-6. PubMed ID: 19932619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Centronuclear myopathy related to dynamin 2 mutations: clinical, morphological, muscle imaging and genetic features of an Italian cohort.
    Catteruccia M; Fattori F; Codemo V; Ruggiero L; Maggi L; Tasca G; Fiorillo C; Pane M; Berardinelli A; Verardo M; Bragato C; Mora M; Morandi L; Bruno C; Santoro L; Pegoraro E; Mercuri E; Bertini E; D'Amico A
    Neuromuscul Disord; 2013 Mar; 23(3):229-38. PubMed ID: 23394783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy.
    Giraud Q; Spiegelhalter C; Messaddeq N; Laporte J
    Brain; 2023 Oct; 146(10):4158-4173. PubMed ID: 37490306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histopathologic changes in the extraocular muscle in centronuclear myopathy with a Dynamin 2 mutation.
    Hanna N; Bouhenni R; Gupta B; Abu-Amero KK; Wollmann R; Edward DP
    Ophthalmic Genet; 2013; 34(1-2):83-6. PubMed ID: 22924779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice.
    Tasfaout H; Lionello VM; Kretz C; Koebel P; Messaddeq N; Bitz D; Laporte J; Cowling BS
    Mol Ther; 2018 Apr; 26(4):1082-1092. PubMed ID: 29506908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen improves muscle structure and function of Bin1- and Dnm2-related centronuclear myopathies.
    Gineste C; Simon A; Braun M; Reiss D; Laporte J
    Brain; 2023 Jul; 146(7):3029-3048. PubMed ID: 36562127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy.
    Trochet D; Prudhon B; Beuvin M; Peccate C; Lorain S; Julien L; Benkhelifa-Ziyyat S; Rabai A; Mamchaoui K; Ferry A; Laporte J; Guicheney P; Vassilopoulos S; Bitoun M
    EMBO Mol Med; 2018 Feb; 10(2):239-253. PubMed ID: 29246969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A centronuclear myopathy-causing mutation in dynamin-2 disrupts neuronal morphology and excitatory synaptic transmission in a murine model of the disease.
    Arriagada-Diaz J; Flores-Muñoz C; Gómez-Soto B; Labraña-Allende M; Mattar-Araos M; Prado-Vega L; Hinostroza F; Gajardo I; Guerra-Fernández MJ; Bevilacqua JA; Cárdenas AM; Bitoun M; Ardiles AO; Gonzalez-Jamett AM
    Neuropathol Appl Neurobiol; 2023 Aug; 49(4):e12918. PubMed ID: 37317811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.